CAM 258

Genetic Testing of Mitochondrial Disorders

Category:Laboratory   Last Reviewed:January 2021
Department(s):Medical Affairs   Next Review:January 2022
Original Date:July 2014    

Description
Mitochondrial disease refers to a heterogeneous group of disorders caused by dysfunctional mitochondria, the organelles responsible for oxidative phosphorylation within the cell. Mitochondrial diseases are classified according to the primary genetic defect, including those affecting respiratory chain proteins or ancillary proteins, mitochondrial RNA translation defects, inner membrane lipid defects, mutations causing depletion of mitochondrial DNA, or mutations to mitochondrial dynamics.  Tissues with high energy demands, such as brain, heart, and skeletal muscle, are most affected by mitochondrial diseases. As a result, mitochondrial encephalopathy and cardiomyopathy are the most prominent manifestations.

Regulatory Status
A search of the FDA database on 10/27/2020 using the terms “mtDNA” and “mitochondrial disease” yielded 0 results. Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88). As an LDT, the U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use.

Policy
Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request 

  1. Genetic testing to confirm the diagnosis of a mitochondrial disorder (e.g. MELAS, MERRF, CPEO, Kearns-Sayre syndrome, Leigh syndrome) is considered MEDICALLY NECESSARY as an alternative to muscle biopsy when clinical signs and symptoms are consistent with a specific mitochondrial disorder but the diagnosis cannot be made with certainty without genetic testing
  2. In patients strongly suspected of having a mitochondrial disorder without symptomology associated with a specific mitochondrial condition, genomic sequencing and large deletion detection of the entire mitochondrial genome with heteroplasmy detection is considered MEDICALLY NECESSARY.
  3. Quantification of mtDNA in tissue to diagnose mtDNA depletion syndromes is considered MEDICALLY NECESSARY.
  4. Genetic counseling for mitochondrial disorder genetic testingis considered MEDICALLY NECESSARY. It is RECOMMENDED but is NOT REQUIRED.

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of a patient’s illness.  

  1. Combination testing testing of mitochondrial genome testing with WES with intronic variants testing and regulatory variants testing, sometimes referred to as whole exome plus testing, including but not limited to Genomic Unity ® Exome Plus Analysis, is considered NOT MEDICALLY NECESSARY.
  2. Combination testing of mitochondrial genome testing with WGS with intronic variants testing and regulatory variants testing, sometimes referred to as Genomic Unity ® Whole Genome Analysis, is considered NOT MEDICALLY NECESSARY.
  3. Genetic testing for mitochondrial disorders is considered NOT MEDICALLY NECESSARY in all other situations.

Rationale
Mitochondrial diseases are generally inherited and present with an elaborate genetic makeup. Several different types of mitochondrial diseases and resulting ailments exist which include “mitochondrial encephalomyopathy, lactic acidosis, and stroke‐like episodes (MELAS), myoclonic epilepsy and ragged‐red‐fibers (MERRF), chronic progressive external ophthalmoplegia (CPEO), Kearns‐Sayre syndrome (KSS), neuropathy, ataxia, and retinitis pigmentosa (NARP), maternally inherited Leigh syndrome (MILS), and Leber hereditary optic neuropathy (LHON)." These diseases can be caused by mutations in either nuclear DNA (nDNA) or mitochondrial DNA (mtDNA); many different mitochondrial disease mutations have been identified, but clinical symptoms are extremely variable and may even differ between patients carrying the same mtDNA mutation. Symptoms present in several areas of the body, including the central nervous system, cardiovascular system, gastrointestinal system, endocrine system, and neuromuscular system.. Clinical differences depend on age of onset, affected organ or tissue, and disease progression. Phenotypic variability and severity can create challenges when diagnosing affected patients.

Pathogenic variants in more than 300 genes have been associated with mitochondria-related disorders. For example, infantile onset of mitochondrial diseases with multiple mitochondrial respiratory chain defects result from mutation(s) in the Required for Meiotic Nuclear Division protein 1 (RMND1) gene. Further, a pathogenic variant in the ubiquinone biosynthesis protein (COQ4) gene has been affiliated with mitochondrial disease development. Patients with mutations in  the NADH dehydrogenase mitochondrial (MT-ND1 and NDUF) genes share phenotypic and genotypic correlations in Leigh Syndrome.The individual symptoms are nonspecific, and symptom patterns can overlap considerably. As a result, a patient often cannot be easily classified into one particular syndrome.

Previously, the prevalence of mitochondrial diseases was considered low. With the advent of advanced genetic analysis tools, numerous studies now report a higher incidence of mitochondrial-associated mutations. A meta-analysis of the prevalence of the three primary mtDNA mutations that cause LHON in Europe shows a prevalence of approximately 1:45,000 (Mascialino, Leinonen, & Meier, 2012). A longitudinal study in Sweden reports an incidence of mitochondrial encephalomyopathies, in general, at 1:11,000, and an incidence of infantile mitochondrial myopathy with cytochrome C oxidase deficiency at 1:51,000. The authors conclude that “mitochondrial encephalomyopathies are relatively common neurometabolic disorders in childhood”.  A 2015 study in the United Kingdom reports that “the total prevalence of adult mitochondrial disease, including pathogenic mutations of both the mitochondrial and nuclear genomes (≈1 in 4,300), is among the commonest adult forms of inherited neurological disorders." An Australian study estimates a “minimum birth prevalence of 13.1/100 000 or 1/7,634 for respiratory chain disorders with onset at any age.”

The evaluation and diagnostic approach for a mitochondrial disorder varies according to age, clinical phenotype, and presumed inheritance pattern. Biochemical testing is indicated for patients who do not have a clear clinical picture of one specific disorder. Measurement of serum lactic acid is often used as a screening test, but the test is neither sensitive nor specific for mitochondrial disorders. “Identifying causative mutations underlying mitochondrial dysfunction is the ultimate gold standard for the diagnosis. Two mitochondrial diseases (MNGIE and coenzyme Q10 deficiency) are particularly important to identify because of potential treatments."

Clinical Utility and Validity
Clinical utility is high for confirming the diagnosis of mitochondrial disorders in people who have clinical features consistent with a specific mitochondrial disease. In these patients, a positive result on genetic testing can avoid a muscle biopsy and eliminate the need for further clinical workup . Additionally, genetic testing may impact reproductive decision making when a defined mitochondrial disease is present in the family that is severe enough to cause impairment and/or disability. If genetic testing is used in this situation, there will be a decreased risk of a mitochondrial disorder in the offspring. Such testing includes whole-exome sequencing, whole-genome sequencing, and whole mitochondrial sequencing. 

The most common first-line diagnostic test for a mitochondrial disease is massively parallel sequencing (MPS), also known as Next-Generation Sequencing (NGS); other accepted methods included targeted panels, whole-exome sequencing (WES) and whole-genome sequencing (WGS). Broad-based exome sequencing has been considered the first-line diagnostic tool for primary mitochondrial disease (PMD), and other researchers have used WES in tandem with rapid mitochondrial genome (mtDNA) sequencing for diagnoses.

WES is likely to increase the detection rate but will also increase the rate of identifying a variant of uncertain significance (VUS). In one study from the U.K., 53 patients who had biochemical evidence of a mitochondrial disorder, but were negative on genetic testing of the primary mitochondrial disorder mutations, underwent whole exome sequencing. Probable pathogenic mutations causative of a mitochondrial disorder were identified in 28 patients (53%), and an additional four patients had variants that were possibly pathogenic. “False negative rates vary by genomic region; therefore, genomic testing may not be as accurate as targeted single gene testing or multigene molecular genetic testing panels. Most laboratories confirm positive results using a second, well-established method."

Expanded panels are defined as panels that include more genes than are associated with any specific disorder. When these panels are used in individuals with nonspecific signs and symptoms that are not consistent with a “classic” presentation of a mitochondrial disorder, the probability of finding a pathogenic mutation is considerably less. Conversely, the likelihood of a false-positive result and the number of VUS (a variant of uncertain significance) may be substantially increased. Table 1, below, lists examples of commercially available expanded genetic panels for mitochondrial disorders.

Table 1. Examples of Commercially Available Expanded Genetic Panels for Mitochondrial Disorders

Laboratory

Lab Test or Panel

Number of Genes Included on Panel

Gene Dx® (Gaithersburg, MD)

MitoXpanded Panel  (GeneDX, 2018b)

~1800

Combined Mito Genome Plus Mito Focused Nuclear Gene Panel (GeneDX, 2018a)

202

Transgenomic® (New Haven, CT)

Nuclear Mitome Test (Transgenomic, 2011)

>400  

ARUP® (Salt Lake City, UT)

Mitochondrial Disorders Panel (ARUP, 2018)

>150

Baylor® Miraca Genetics Laboratories (Houston, TX)

Mitome Nuclear Genes (BMGL, 2015)

164

Medical Neurogenetics® (Atlanta, GA)

Mitochondrial Genome Sequencing & Deletion Analysis (Medical Neurogenetics, 2018)

>300

Wood et al. (2019) recently compared the mtDNA sequencing results of the long-read sequencing technology Oxford Nanopore Technologies (ONT) MinION to the Illumina MiSeq, a next generation sequencing platform. A total of 12 patients participated in this study (three healthy controls and nine with known mtDNA deletion disorders). Both of these next-generation sequencing methods were more efficient than LR-PCR and/or Southern Blotting; further, MinION proved to be just as accurate as the Illumina MiSeq in this study, successfully identifying all mtDNA deletions. This tool may assist in making the mitochondrial disease diagnostic process more efficient and cost effective in the future.

Wagner et al. (2019) researched the effectiveness of exome sequencing (ES) for mitochondrial disease diagnostics; data was used from 2111 clinical cases. The researchers stated that “ES identified known pathogenic mtDNA point mutations in 38 individuals, increasing the diagnostic yield by nearly 2%. Analysis of mtDNA variants by ES had a high recall rate (96.2 ± 5.6%) and excellent precision (99.5 ± 2.2%) when compared to the gold standard of targeted mtDNA next generation sequencing. These results suggest that ES should be considered as a diagnostic tool for both nDNA and mtDNA testing.

Legati et al. (2016) suggest a two-tiered approach to genetic testing where targeted NGS is used first in cases of suspected mitochondrial disorders followed by WES in patients who have inconclusive results. “Importantly, WES on selected cases has unraveled the presence of pathogenic mutations in genes encoding non-mitochondrial proteins (e.g. the transcription factor E4F1), an observation that further expands the intricate genetics of mitochondrial disease and suggests a new area of investigation in mitochondrial medicine.”

Pronicka et al. (2016) suggest that whole-exome sequencing (WES) is a better diagnostic tool than NGS. A total of 113 pediatric Polish patients participated in this study; variants were identified in both nDNA and mtDNA. WES was able to identify “likely causative mutations” in 67 patients, with 50.5% of all detected genetic changes novel variants; further, “In 47 patients, changes in 31 MD-related genes (ACAD9, ADCK3, AIFM1, CLPB, COX10, DLD, EARS2, FBXL4, MTATP6, MTFMT, MTND1, MTND3, MTND5, NAXE, NDUFS6, NDUFS7, NDUFV1, OPA1, PARS2, PC, PDHA1, POLG, RARS2, RRM2B, SCO2, SERAC1, SLC19A3, SLC25A12, TAZ, TMEM126B, VARS2) were identified.”

In a study by Kerr et al. (2020), 390 patients were recruited and tested for mitochondrial disease (MD) through traditional diagnostic pathways (metabolite analysis, tissue neuropathology and respiratory chain enzyme activity) and new diagnostic approaches (next generation sequencing (NGS) and nuclear whole exome sequencing (nWES)). Testing through traditional diagnostic methods resulted in a mitochondrial diagnosis in 115 out of 390 patients (29.50%). In comparison, 116 out of 390 patients were recruited for NGS, which identified 36 patients (31%) with a mitochondrial diagnosis. To confirm diagnosis, patients were further tested through nuclear whole exome sequencing (nWES), which provided a secondary diagnosis in “two cases who already had a pathogenic variant in mtDNA, and a revised diagnosis (GLUL) in one case that had abnormal pathology but no pathogenic mtDNA variant”. nWES also identified a mitochondrial diagnosis in one patient who tested negative from NGS. The author offers a diagnostic evaluation strategy, as shown in the figure below, and recommends that “a non-invasive, bigenomic sequencing (BGS) approach (using both a nWES and optimized mtDNA analysis to include large deletions) should be the first step in investigating for mitochondrial diseases. There may still be a role for tissue biopsy in unsolved cases or when the diagnosis is still not clear after NGS studies”

Another study clearly demonstrates the heterogeneity of genetic mutations causing mitochondrial disorders. Of the 142 patients with childhood-onset mitochondrial disorders, researchers “identified 37 novel mutations in known mitochondrial disease genes and 3 mitochondria-related genes (MRPS23, QRSL1, and PNPLA4) as novel causative genes."  These researchers utilized whole mtDNA and exome and chromosomal aberration analysis approaches to “enhance the ability to identify pathogenic gene mutations in patients”.

A study by Fang et al. (2017) recruited 141 children with suspected mitochondrial disorders and used NGS to identify genetic characteristics. Forty children were gene confirmed with a known mitochondrial disease; 62.5% of those cases were due to a mtDNA mutation and 37.5% due to a nDNA mutation. This study found the most prevalent disorders to be Leigh Syndrome and MELAS.).

Mitochondrial Medicine Society
The Mitochondrial Medicine Society published the following consensus recommendations on genetic testing for mitochondrial disorders:

  1. “Massively parallel sequencing/NGS of the mtDNA genome is the preferred methodology when testing mtDNA and should be performed in cases of suspected mitochondrial disease instead of testing for a limited number of pathogenic point mutations.
  2. Patients with a strong likelihood of mitochondrial disease because of a mtDNA mutation and negative testing in blood, should have mtDNA assessed in another tissue to avoid the possibility of missing tissue-specific mutations or low levels of heteroplasmy in blood; tissue-based testing also helps assess the risk of other organ involvement and heterogeneity in family members and to guide genetic counseling.
  3. Heteroplasmy analysis in urine can selectively be more informative and accurate than testing in blood alone, especially in cases of MELAS due to the common m. 3243A>G mutation.
  4. mtDNA deletion and duplication testing should be performed in cases of suspected mitochondrial disease via NGS of the mtDNA genome, especially in all patients undergoing a diagnostic tissue biopsy.
    1. If a single small deletion is identified using polymerase chain reaction–based analysis, then one should be cautious in associating these findings with a primary mitochondrial disorder.
    2. When multiple mtDNA deletions are noted, sequencing of nuclear genes involved in mtDNA biosynthesis is recommended.
  5. When a tissue specimen is obtained for mitochondrial studies, mtDNA content (copy number) testing via real-time quantitative polymerase chain reaction should strongly be considered for mtDNA depletion analysis because mtDNA depletion may not be detected in blood.
    1. mtDNA proliferation is a nonspecific compensatory finding that can be seen in primary mitochondrial disease, secondary mitochondrial dysfunction, myopathy, hypotonia, and as a by-product of regular, intense exercise.
  6. When considering nuclear gene testing in patients with likely primary mitochondrial disease, NGS methodologies providing complete coverage of known mitochondrial disease genes is preferred. Single-gene testing should usually be avoided because mutations in different genes can produce the same phenotype. If no known mutation is identified via known NGS gene panels, then whole exome sequencing should be considered.”

The Mitochondrial Medicine Society also commented on the set of mtDNA depletion syndromes, which are “characterized by a significant reduction in mtDNA copy number in affected tissues”. They note that diagnosis of these conditions “requires quantification of mtDNA content, typically in affected tissue, with identification of a significant decrease below the mean of normal age, gender, and tissue-specific control when normalized to nDNA tissue content”. Since NGS of the mtDNA genome does not identify mtDNA content, a separate quantitative real-time polymerase chain reaction must be used .

The Mitochondrial Medicine Society in 2017 released their guidelines regarding patient care standards.  Within this set of guidelines, they state, “Pregnancy in mitochondrial disease also elicits the concern of transmission of a genetic disorder. Appropriate preconception genetic counseling and discussion of options of prenatal testing are needed. A fetus affected by mitochondrial disease may also be at higher risk for prenatal morbidity. Finally, premature ovarian failure is a feature of several mitochondrial disorders and affected women should be referred for assisted reproductive technologies if they wish to have children”

European Academy of Neurology (EAN)
Regarding genetic testing for mitochondrial encephalopathy, lactic acidosis and stroke‐like episodes (MELAS), the EAN recommends “Urgent genetic testing for MELAS should be considered in patients presenting with suspected SLE (stroke‐like episode). Search for the m.3243A>G variant (in urine where possible) and, if m.3243A>G variant is negative, POLG sequencing is required. Muscle biopsy should be considered after excluding m.3243A>G and POLG variants.” The EAN also notes that valproic acid is “contraindicated, mainly in patients with POLG variants”.

MNGIE International Network
The MNGIE (Mitochondrial neurogastrointestinal encephalomyopathy) International Network recommended TYMP sequencing to confirm a MNGIE diagnosis. If a variant of unknown significance or a wild-type variant is found, the Network recommends biochemical testing of thymidine (dThd) and deoxyuridine levels to determine thymidine phosphorylase (TP) activity. The Network also remarks on several treatment options (both short- and long-term), which focus on restoring the biochemical balance of the patient.

References  

  1. Akesson, L., Eggers, S., Chong, B., Hunter, M., Krzesinski, E., Brown, N., . . . Lunke, S. (2019). Rapid mitochondrial genome (MTDNA) sequencing: facilitating rapid diagnosis of mitochondrial diseases in paediatric acute care. 51, 118–S119. Retrieved from https://www.pathologyjournal.rcpa.edu.au/article/S0031-3025(18)31004-3/abstract
  2. ARUP. (2018, 06/04/2018). Mitochondrial Disorders Panel (mtDNA Sequencing, Nuclear Genes Sequencing, and Deletion/Duplication). Retrieved from http://ltd.aruplab.com/Tests/Pub/2006054
  3. BMGL. (2015, 08/03/2015). MITOCHONDRIAL DNA (mtDNA) TEST REQUISITION. Retrieved from https://www.bcm.edu/research/medical-genetics-labs/index.cfm?pmid=26409
  4. Chinnery, P. F. (2014). Mitochondrial Disorders Overview. In M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, & A. Amemiya (Eds.), GeneReviews((R)) (Vol. 2014 update). Seattle (WA): University of Washington, Seattle
  5. University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.
  6. Darin, N., Oldfors, A., Moslemi, A. R., Holme, E., & Tulinius, M. (2001). The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol, 49(3), 377-383.
  7. Dimmock, D. P., & Lawlor, M. W. (2017). Presentation and Diagnostic Evaluation of Mitochondrial Disease. Pediatr Clin North Am, 64(1), 161-171. doi:10.1016/j.pcl.2016.08.011
  8. Fang, F., Liu, Z., Fang, H., Wu, J., Shen, D., Sun, S., . . . Shen, Y. (2017). The clinical and genetic characteristics in children with mitochondrial disease in China. Sci China Life Sci, 60(7), 746-757. doi:10.1007/s11427-017-9080-y
  9. FMM. (2018). Diagnosis And Treatments. Mitochondrial Disease. Retrieved from http://mitochondrialdiseases.org/mitochondrial-disease/diagnosis-and-treatments/
  10. GeneDX. (2018a, 03/2018). MITOCHONDRIAL GENE TABLE. Retrieved from https://www.genedx.com/wp-content/uploads/crm_docs/200246_Mitochondrial-Gene-Table-1.pdf
  11. GeneDX. (2018b, 05/2018). MITOXPANDED PANEL GENE LIST. Retrieved from https://www.genedx.com/wp-content/uploads/2018/05/40355_MitoXpanded-Panel-Gene-List-table.pdf
  12. Gorman, G. S., Schaefer, A. M., Ng, Y., Gomez, N., Blakely, E. L., Alston, C. L., . . . McFarland, R. (2015). Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol, 77(5), 753-759. doi:10.1002/ana.24362
  13. Hatakeyama, H., & Goto, Y. (2016). Concise Review: Heteroplasmic Mitochondrial DNA Mutations and Mitochondrial Diseases: Toward iPSC-Based Disease Modeling, Drug Discovery, and Regenerative Therapeutics. Stem Cells, 34(4), 801-808. doi:10.1002/stem.2292
  14. Hirano, M., Carelli, V., De Giorgio, R., Pironi, L., Accarino, A., Cenacchi, G., . . . Zeviani, M. (2020). Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the MNGIE International Network. J Inherit Metab Dis. doi:10.1002/jimd.12300
  15. Horvath, R., & Chinnery, P. (2019). Diagnostic Approach to Mitochondrial Diseases.
  16. Kerr, M., Hume, S., Omar, F., Koo, D., Barnes, H., Khan, M., . . . Khan, A. (2020). MITO-FIND: A study in 390 patients to determine a diagnostic strategy for mitochondrial disease. Molecular Genetics and Metabolism. doi:https://doi.org/10.1016/j.ymgme.2020.08.009
  17. Kohda, M., Tokuzawa, Y., Kishita, Y., Nyuzuki, H., Moriyama, Y., Mizuno, Y., . . . Okazaki, Y. (2016). A Comprehensive Genomic Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex Deficiencies. PLoS Genet, 12(1), e1005679. doi:10.1371/journal.pgen.1005679
  18. Legati, A., Reyes, A., Nasca, A., Invernizzi, F., Lamantea, E., Tiranti, V., . . . Zeviani, M. (2016). New genes and pathomechanisms in mitochondrial disorders unraveled by NGS technologies. Biochim Biophys Acta, 1857(8), 1326-1335. doi:10.1016/j.bbabio.2016.02.022
  19. Lightowlers, R. N., Taylor, R. W., & Turnbull, D. M. (2015). Mutations causing mitochondrial disease: What is new and what challenges remain? Science, 349(6255), 1494-1499. doi:10.1126/science.aac7516
  20. Ling, T.-k., Law, C.-y., Ko, C.-h., Fong, N.-c., Wong, K.-c., Lee, K.-l., . . . Lam, C.-w. (2019). A common COQ4 mutation in undiagnosed mitochondrial disease: a local case series. 51, S112–S113. Retrieved from https://www.pathologyjournal.rcpa.edu.au/article/S0031-3025(18)30982-6/abstract
  21. Mancuso, M., Arnold, M., Bersano, A., Burlina, A., Chabriat, H., Debette, S., . . . Markus, H. S. (2020). Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology. Eur J Neurol, 27(6), 909-927. doi:10.1111/ene.14183
  22. Mascialino, B., Leinonen, M., & Meier, T. (2012). Meta-analysis of the prevalence of Leber hereditary optic neuropathy mtDNA mutations in Europe. Eur J Ophthalmol, 22(3), 461-465. doi:10.5301/ejo.5000055
  23. McCormick, E. M., Zolkipli-Cunningham, Z., & Falk, M. J. (2018). Mitochondrial disease genetics update: recent insights into the molecular diagnosis and expanding phenotype of primary mitochondrial disease. Curr Opin Pediatr, 30(6), 714-724. doi:10.1097/mop.0000000000000686
  24. Medical Neurogenetics, L. (2018). MITOCHONDRIAL GENOME SEQUENCING. Retrieved from https://mnglabs.com/individual-test-page/?q=108
  25. Meyers, D. E., Basha, H. I., & Koenig, M. K. (2013). Mitochondrial cardiomyopathy: pathophysiology, diagnosis, and management. Tex Heart Inst J, 40(4), 385-394.
  26. Ng, Y. S., Alston, C. L., Diodato, D., Morris, A. A., Ulrick, N., Kmoch, S., . . . McFarland, R. (2016). The clinical, biochemical and genetic features associated with RMND1-related mitochondrial disease. J Med Genet, 53(11), 768-775. doi:10.1136/jmedgenet-2016-103910
  27. O'Brien, M., Cryan, J., Brett, F., Howley, R., & Farrell, M. (2014). Ten years on: genetic screening for mitochondrial disease in Ireland. Clin Neuropathol, 33(4), 279-283. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=Ten+years+on%3A+genetic+screening+for+mitochondrial+disease+in+Ireland
  28. O'Ferrall, E. (2019). Mitochondrial myopathies: Clinical features and diagnosis. UpToDate. Retrieved from https://www.uptodate.com/contents/mitochondrial-myopathies-clinical-features-and-diagnosis
  29. Parikh, S., Goldstein, A., Karaa, A., Koenig, M. K., Anselm, I., Brunel-Guitton, C., . . . Chinnery, P. F. (2017). Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med, 19(12). doi:10.1038/gim.2017.107
  30. Parikh, S., Goldstein, A., Koenig, M. K., Scaglia, F., Enns, G. M., Saneto, R., . . . DiMauro, S. (2015). Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med, 17(9), 689-701. doi:10.1038/gim.2014.177
  31. Pronicka, E., Piekutowska-Abramczuk, D., Ciara, E., Trubicka, J., Rokicki, D., Karkucinska-Wieckowska, A., . . . Ploski, R. (2016). New perspective in diagnostics of mitochondrial disorders: two years' experience with whole-exome sequencing at a national paediatric centre. J Transl Med, 14(1), 174. doi:10.1186/s12967-016-0930-9
  32. Schon, E. A., DiMauro, S., & Hirano, M. (2012). Human mitochondrial DNA: roles of inherited and somatic mutations. Nat Rev Genet, 13(12), 878-890. doi:10.1038/nrg3275
  33. Skladal, D., Halliday, J., & Thorburn, D. R. (2003). Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain, 126(Pt 8), 1905-1912. doi:10.1093/brain/awg170
  34. Sofou, K., de Coo, I. F. M., Ostergaard, E., Isohanni, P., Naess, K., De Meirleir, L., . . . Darin, N. (2018). Phenotype-genotype correlations in Leigh syndrome: new insights from a multicentre study of 96 patients. J Med Genet, 55(1), 21-27. doi:10.1136/jmedgenet-2017-104891
  35. Taylor, R. W., Pyle, A., Griffin, H., Blakely, E. L., Duff, J., He, L., . . . Chinnery, P. F. (2014). Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. Jama, 312(1), 68-77. doi:10.1001/jama.2014.7184
  36. Thompson, K., Collier, J., Glasglow, R., Robertson, F., Pyle, A., Blakely, E., . . . Taylor, R. W. (2019). Recent advances in understanding the molecular genetic basis of mitochondrial disease. Retrieved from https://onlinelibrary.wiley.com/doi/full/10.1002/jimd.12104
  37. Transgenomic, I. (2011). Transgenomic, Inc. Launches Best-in-Class Next-Generation Sequencing Test for Nuclear Mitochondrial Disorders at the 2011 United Mitochondrial Disease Foundation Meeting. PR Newswire. Retrieved from https://www.prnewswire.com/news-releases/transgenomic-inc-launches-best-in-class-next-generation-sequencing-test-for-nuclear-mitochondrial-disorders-at-the-2011-united-mitochondrial-disease-foundation-meeting-123996704.html
  38. Wagner, M., Berutti, R., Lorenz-Depiereux, B., Graf, E., Eckstein, G., Mayr, J. A., . . . Wortmann, S. B. (2019). Mitochondrial DNA mutation analysis from exome sequencing-A more holistic approach in diagnostics of suspected mitochondrial disease. J Inherit Metab Dis, 42(5), 909-917. doi:10.1002/jimd.12109
  39. Wood, E., Parker, M., Dunning, M., Hesketh, S., Wang, D., Pink, R., & Fratter, C. (2019). Clinical long-read sequencing of the human mitochondrial genome for mitochondrial disease diagnostics. Retrieved from https://www.biorxiv.org/content/10.1101/597187v1.full

Coding Section

Code Number

Code Description

81401

Molecular pathology procedure, Level 2

81403

Molecular pathology procedure, Level 4

81440

Nuclear encoded mitochondrial genes (eg, neurologic or myopathic phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP

81460

Whole mitochondrial genome (eg, Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers [MERFF], neuropathy, ataxia, and retinitis pigmentosa [NARP], Leber hereditary optic neuropathy [LHON]), genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection. 

81465

Whole mitochondrial genome large deletion analysis panel (eg, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia), including heteroplasmy detection, if performed

96040 

Medical genetics and genetic counseling services, each 30 minutes face-to-face with patient/family 

S0265

Genetic counseling, under physician supervision, each 15 minutes

0212U

Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband
Proprietary test: Genomic Unity® Whole Genome Analysis - Proband
Lab/Manufacturer: Variantyx Inc

0213U

Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent, sibling)
Proprietary test: Genomic Unity® Whole Genome Analysis - Comparator
Lab/Manufacturer: Variantyx Inc

0214U

Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband
Proprietary test: Genomic Unity® Exome Plus Analysis - Proband
Lab/Manufacturer: Variantyx Inc

0215U

Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling)
Proprietary test: Genomic Unity® Exome Plus Analysis - Comparator
Lab/Manufacturer: Variantyx Inc

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies and accredited national guidelines.

"Current Procedural Terminology© American Medical Association.  All Rights Reserved" 

History From 2014 Forward     

01/22/2021 

Annual review, reformatting for clarity, updating policy number. Adding medical necessity criteria for mtDNA testing, adding criteria 5 and 6 related to WES testing. Also updating description, rationale, references and coding. 

01/02/2020 

Annual review, no change to policy intent. 

09/24/2019 

Updated coding. No other changes made. 

01/10/2019 

Annual review, updating medical necessity criteria for clarity. 

01/25/2018 

Annual review. Updating medical necessity for clarity of disorders to be tested. No change to policy intent. Updating rationale, references and guidelines. 

04/27/2017 

Annual review, updating category to laboratory. Updating policy verbiage and guidelines related to specific mutations. 

04/26/2017 

Interim review to align with Avalon quarterly schedule. Updated category to Laboratory. 

07/12/2016 

Annual review, no change to policy intent. Updating background, description, rationale, references and appendix 1. 

07/27/2015 

Annual review, no change to policy intent. Reorganizing policy and guideline verbiage, but NOT changing intent. Updated background, description, rationale and references. Added coding and appendix 1.

07/07/2014

New Policy 


Go Back